Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy (ATHETOID_CD)

August 19, 2017 updated by: Keewon Kim, Seoul National University Hospital

A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy

This study aimed to compare the efficacy and safety of Meditoxin® injection for cervical dystonia in adults with cerebral palsy. It is a placebo controlled, Cross-over, Double blind, Randomized, Clinical trial.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

17

Phase

  • Phase 4

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult cerebral palsy patients over 20 years old
  • Clinically diagnosed for cervical dystonia more than a year ago
  • No improvement with antispasmodics for the last month
  • Actively participated and gave informed consent

Exclusion Criteria:

  • Allergic to the botulinum toxin
  • Limited range of motion in cervical spine
  • Patients with fever, infection, cancer, uncontrollable seizure
  • Generalized neuromuscular junction disease patients
  • Pregnant or breast feeding women, or anticipating pregnancy until 12 weeks after the study stopped
  • Patients enrolled in other studies
  • History of dose change in 4 weeks: antispasmodics, benzodiazepine, anticholinergics
  • Botulinum toxin injection history in 6 months
  • Previous history of intrathecal baclofen, selective peripheral denervation, deep brain stimulation
  • Otherwise clinically non-eligible patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Treatment-Placebo Group
Treatment on 0 day Placebo at 5th week
Drug: Meditoxin
Active Comparator: Placebo-Treatment Group
Placebo on 0 day Treatment at 5th week
Drug: Normal saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
Time Frame: 0, 16, 32 weeks
Change of Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) from baseline TWSTRS at 0 week.
0, 16, 32 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain in numerical rating scale (NRS)
Time Frame: Every 4 weeks, up to 32 weeks
Pain in numerical rating scale (NRS)
Every 4 weeks, up to 32 weeks
Japanese Orthopaedic Association (JOA) score
Time Frame: Every 4 weeks, up to 32 weeks
Change of Japanese Orthopaedic Association (JOA) score from baseline Japanese Orthopaedic Association (JOA) score at 0 week.
Every 4 weeks, up to 32 weeks
Goal attainment scale
Time Frame: 4, 12, 20, 28 weeks
Goal attainment scale of subjective improvement from the baseline status at 0 and 16 weeks.
4, 12, 20, 28 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse effect
Time Frame: Every 4 weeks, up to 32 weeks
vital sign, adverse effect
Every 4 weeks, up to 32 weeks
computed tomography (CT)
Time Frame: 0, 32 weeks
Change of cervical spine computed tomography (CT) from baseline CT at 0 week.
0, 32 weeks
videofluoroscopic swallowing study (VFSS)
Time Frame: 0, 12, 28 weeks
Change of videofluoroscopic swallowing study (VFSS) from baseline VFSS at 0 week.
0, 12, 28 weeks
Blood/Urine laboratory tests
Time Frame: 0, 16, 32 weeks
  1. Hemoglobin, Hematocrit, RBC, WBC, WBC different cell count, Platelet
  2. Alkaline phosphatase, BUN, Creatinine, SGPT(ALT), SGOT(AST), Albumin, Total protein, Total bilirubin, Uric acid, Glucose, Cholesterol, LDH, Na, Ca, K, Cl
  3. Urine pH, Protein, Glucose, Bilirubin, Blood, WBC
0, 16, 32 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seoul National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

June 1, 2017

Study Registration Dates

First Submitted

May 13, 2013

First Submitted That Met QC Criteria

May 19, 2013

First Posted (Estimate)

May 22, 2013

Study Record Updates

Last Update Posted (Actual)

August 22, 2017

Last Update Submitted That Met QC Criteria

August 19, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MT_IT_009

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adult Cerebral Palsy

Clinical Trials on Normal saline

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe